Population Antibacterial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

We also need a robust pipeline of discovery thatll lead to new drug candidates for all different kinds of infections. So the limited population idea and the streamlining of Clinical Trials which wouldnt just decrease the time frame, it also decreases the cost and the, you know, the number of people needed, so it would do a number of things, that is one thing that we can do at fda that we think would be beneficial and would be beneficial for patients, but its not going to fix this problem we have of investment. Thank you, mr. Chairman. I yield back. I think that concludes this round of question...

Them harder. I think we would welcome legislation to reform that area. But if we come in a blunt instrument, suddenly recreating the fda authorities or mandating things on the fda or looking for the department of health and Human Services to do things that theyre not equipped to do and then, of course, we dont fund them to do it, i think we have to be cautious about some of the legislation that may be proposed. More than anything we want government to be there to work collaboratively but we still have to recognize the safety and efficacy that American People and most people here would certainl...

Representatives of disease groups know more about the diseases than anybody else. They have worked so hard to try to understand whats at stake. Pressing the government to be as flexible as possible. I think its important for the infrastructure for the 21st century cures. I want to say i would be a little cautious about thinking we can solve big problems with legislation with all the unforeseen consequences that can sit inn at a panel here ten years from now and bemoan. I guess thats not a question, but comments. I thank the witnesses and particularly, my good friend and constituent mike milken...

40 years. One, putting the patients at the center of discovery, development and delivery process. More efficient Clinical Trials. Meaningful working relationships between patients. And diseasespecific organizations. One of the great advancements of the past two decades has been the strengthening and improvement of the disease Recognition Research group. Two, incentivize collaboration across sectors in the r d process. Public private partnership. Look at history books and see those partnerships between ford and kaiser and the government that allowed us to have victory in world war ii as we move...

This week is World Antimicrobial Awareness Week, a global campaign initiated by the World Health Organization (WHO) to improve awareness and understanding of AMR, yet only 44 percent of people have heard of AMR. We considered the portrayal of AMR in the media to determine how this might affect public consciousness and tangible action to tackle AMR.